Not checkedNot checked for notices yet.
Comparative proteomic analysis of differentiated thyroid carcinoma and radioiodine-refractory differentiated thyroid carcinoma based on iTRAQ technique
LI Yunjie, HUANG Xin, DENG Jie and 1 more
Di-san junyi daxue xuebao · 2019
doi:10.16016/j.1000-5404.201907087 (opens in a new tab)
We email you when a new notice or a question about this paper appears.
Abstract
Objective To identify the differentially expressed proteins between differentiated thyroid carcinoma and radioiodine-refractory differentiated thyroid carcinoma, explore the pathogenetic mechanism of radioiodine-refractory differentiated thyroid carcinoma, and identify potential targets for nuclide molecular therapy. Methods We collected the samples of metastatic lymph nodes from 3 patients with radioiodine-refractory differentiated thyroid carcinoma and 3 patients with differentiated thyroid carcinoma treated in our department between June, 2018 and March, 2019. The differential proteins were detected using iTRAQ technique coupled with mass spectrometry. The raw data of iTRAQ were analyzed with a bioinformatic approach for annotating the function of the differential proteins using GO database and analyzing the interaction of the proteins in KEGG signaling pathways. Some of the differential proteins were verified by analysis of TCGA and TCPA databases. Results We identified a total of 665 differential proteins between the 2 cancers, including 327 significantly up-regulated proteins and 338 down-regulated proteins. The differential proteins, including ECM1, CHI3L1, LAMA5, 14-3-3 eta, CDC42, RAC2, and MYL9, participated in the regulation of tumor angiogenesis, invasion, metastasis, and cell dedifferentiation. The differential proteins were significantly enriched in multiple signaling pathways involved in cell metabolism, focal adhesion, and other cell processes. Conclusion Many proteins are differentially expressed between differentiated thyroid carcinoma and radioiodine-refractory differentiated thyroid carcinoma. These proteins are involved in the regulation of the activity of transporters and enzymes and participate in multiple biological processes. Among these differential proteins, ECM1, CHI3L1, and CDC42 promote tumor progression by interacting with the proteins in the MAPK signaling pathway, and may serve as potential targets for radionuclide therapy
Abstract licence: CC BY
Reads
Read by people on this page
None yet.
Checked or read by AI through naulon
None yet.
A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.
Are you an author?
Is this your paper?
Claim it to add your note and be paid when agents cite it. Free.